New Drug-Radiation combo tested for tough pancreatic tumors
NCT ID NCT07157033
Summary
This early-stage study is testing whether a new drug called XER-001, delivered directly to the small intestine, can be safely combined with precise radiation therapy for pancreatic cancer that hasn't spread. Researchers want to find the best dose and see if this combination helps control the tumor. The study is for people whose pancreatic cancer is locally advanced and who have already completed initial chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Christus St. Vincent Regional Cancer Center
RECRUITINGSanta Fe, New Mexico, 87505, United States
Contact
Contact Email: •••••@•••••
-
Oncology Consultants, P.A.
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.